NATCO announces launch of its 10mg strength for Everolimus Tablets in the US market

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that its marketing partner Breckenridge Pharmaceutical, Inc., US has launched the 10mg strength of Everolimus Tablets (generic for Afinitor®) in the US market. The U.S. Food and Drug Administration previously granted final approval of this Abbreviated New Drug Application. According to industry sales data, the 10mg strength of Afinitor generated annual sales of $392 million during the twelve months ending July 2021. Breckenridge previously launched Everolimus tablets in 2.5mg, 5mg and 7.5mg strengths during the first quarter of 2021 in the US market.

Shares of Natco Pharma Ltd. was last trading in BSE at Rs. 889.2 as compared to the previous close of Rs. 886.35. The total number of shares traded during the day was 8904 in over 940 trades.

The stock hit an intraday high of Rs. 894.6 and intraday low of 879.1. The net turnover during the day was Rs. 7891160.

Source : Equity Bulls

Keywords